Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01108445 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT01108445 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 131 participants.
The verdict
NCT01108445, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
Interventions
- DRUG Everolimus
- DRUG Sunitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2010-09 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01108445
The ClinicalTrials.gov registry entry for NCT01108445 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT01108445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01108445 about?
NCT01108445 is a clinical study titled "Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma". To compare the anti-tumor activity of everolimus and sunitinib in subjects with metastatic renal cell carcinoma (mRCC) with non-clear cell pathology.
What is the current status of trial NCT01108445?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2010-09. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01108445?
The interventions under investigation include: Everolimus (DRUG), Sunitinib (DRUG).
Who is sponsoring clinical trial NCT01108445?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.